Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    14-October-2000      
Issue 184 Next Update - 14:00 UTC 08:00 EST    15-October-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya



















Back To Vidyya Today In Vidyyasm

Vidyya Medical News Service For 14-October-2000:

The National Institutes of Health (NIH) called an early halt to one arm of a study on the advice of an independent data and safety monitoring board after finding that people with kidney disease and protein in their urine were more likely to postpone kidney failure using either an ACE inhibitor or a beta blocker than a calcium channel blocker (CCB).

The FDA has approved Novantrone (mitoxantrone), an approved cancer drug, for treating patients with advanced or chronic Multiple Sclerosis (MS), a disease that attacks the nervous system and can cause weakness, impaired vision, loss of balance, and poor muscle coordination. MS can have different patterns, sometimes leaving patients relatively well after episodes of acute worsening, sometimes leading to progressive disability that persists after episodes of worsening. In the worst cases the disease can lead to paralysis.

Two randomized multi-center clinical studies, totaling about 200 patients, demonstrated that Novantrone could reduce the number of relapse episodes and decrease the progression of disability in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting MS (all forms of the disease in which patients become significantly more abnormal between relapses as time passes). Get the prescribing information you need in today's Vidyya.

The Food and Drug Administration (FDA) is announcing two decisions on health claims that were the subject of a court decision. One proposed claim that stated 0.8 mg of folic acid in a dietary supplement was more effective in reducing the risk of neural tube defects than a lower amount in foods was not authorized. The second proposed health claim about dietary fiber and reduced risk of colrectal cancer could not be substantiated.

Diabetics should be among the first in line to receive their flu shots this year, putting special importance on it because of the delay in the availability of the shots. The U.S. Centers for Disease Control and Prevention (CDC) recommends vaccination for those aged 50 and older and people with diabetes, among other chronic diseases.

The articles in today's Vidyya are:

As always, we hope you enjoy the issue.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.